Tryptamine Therapeutics (AU:TYP) has released an update.
Tryptamine Therapeutics, an innovative biotech firm, is alerting holders of its unlisted warrants expiring on 22 July 2024 to submit their exercise forms and payments by the deadline. The company, which recently completed a Phase 2a clinical trial with a significant reduction in binge eating episodes, is advancing treatments for unmet medical needs by developing psilocin-based therapies. Their leading program, TRP-8803, aims to improve the delivery and efficacy of psychedelic treatments, with ongoing clinical trials for conditions such as fibromyalgia and irritable bowel syndrome.
For further insights into AU:TYP stock, check out TipRanks’ Stock Analysis page.
